Philip D. Poorvu

A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial.

Combined intermittent fasting and exercise intervention in patients with metastatic, hormone receptor-positive breast cancer (FastER): a pilot study

Estrogen levels in young women with hormone receptor-positive breast cancer on ovarian function suppression therapy

A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer

Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis

Trajectories of fear of cancer recurrence in young breast cancer survivors

Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors

Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer

Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants

Treatment-related amenorrhea in a modern, prospective cohort study of young women with breast cancer

Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer

Pregnancy After Breast Cancer in Patients With Germline <i>BRCA</i> Mutations

Pregnancy after breast cancer: Results from a prospective cohort of young women with breast cancer

Surgical Treatment After Neoadjuvant Systemic Therapy in Young Women With Breast Cancer

Response to neoadjuvant chemotherapy and the 21-gene breast recurrence score in young women with estrogen receptor-positive early breast cancer.

Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer